BioCentury
ARTICLE | Finance

CRISPRing out new targets

Where investors think CRISPR drug discovery play KSQ can go with platform

October 6, 2017 10:13 PM UTC

Flagship Pioneering believes the CRISPRomics drug discovery technology of recently unveiled KSQ Therapeutics Inc. may have the potential to greatly reduce false positives in drug discovery.

On Oct. 2, KSQ emerged from stealth mode with a $76 million financing led by Flagship. Also participating were fellow founding investor Polaris Partners, Arch Venture Partners and Alexandria Equities. The financing includes a series A and B round that are not broken out. ...

BCIQ Company Profiles

KSQ Therapeutics Inc.